KDEV Karolinska Development AB

Karolinska Development Annual Report 2024 published

Karolinska Development Annual Report 2024 published

STOCKHOLM, SWEDEN – March 21, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2024.

The report is now available to download at

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB

Phone: 2, e-mail:

Hans-Christoffer “HC” Toll, CFO, Karolinska Development AB

Phone: +46 70 717 00 41, e-mail:

TO THE EDITORS

About Karolinska Development AB



Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit

Attachments



EN
21/03/2025

Underlying

KDEVKarolinska Development AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Karolinska Development AB

 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Development Annual Report 2024 published

Karolinska Development Annual Report 2024 published STOCKHOLM, SWEDEN – March 21, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2024. The report is now available to download at For further information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: 2, e-mail: Hans-Christoffer “HC” Toll, CFO, Karolinska Development AB Phone: +46 70 717 00 41, e-mail: TO THE EDITORS About Karolinska Development ABKarolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The com...

21h / 40m 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Developments årsredovisning för 2024 har publicerats

Karolinska Developments årsredovisning för 2024 har publicerats STOCKHOLM, SVERIGE 21 mars 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att årsredovisningen för 2024 har offentliggjorts. Årsredovisningen finns nu tillgänglig på För ytterligare information, vänligen kontakta: Viktor Drvota, vd, Karolinska Development ABTel: +46 73 982 52 02, e-mail: Hans-Christoffer ”HC” Toll, finansdirektör, Karolinska Development AB Phone: +46 70 717 00 41, e-mail: TILL REDAKTÖRERNA Om Karolinska Development ABKarolinska Development AB (Nasdaq Stockholm: KDEV) är ett no...

21h / 40m 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Development’s portfolio company Umecrine Cognition provides...

Karolinska Development’s portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study STOCKHOLM, SWEDEN – March 18, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has provided an update regarding the ongoing clinical phase 1b/2a trial evaluating the drug candidate golexanolone in PBC patients. Due to technical issues in the production of capsules used in the study, the clinical trial has been delayed. No patient safety concerns have been noted, and Umecrine Cognition is working intensively ...

March 18, 2025 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Developments portföljbolag Umecrine Cognition lämnar uppdat...

Karolinska Developments portföljbolag Umecrine Cognition lämnar uppdatering om pågående klinisk fas 1b/2a-studie STOCKHOLM, SVERIGE 18 mars 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition lämnat en uppdatering om den pågående kliniska fas 1b/2a-studien av golexanolon i patienter med primär biliär kolangit, PBC. På grund av tekniska problem i produktionen av de kapslar som används i studien har tidsplanen försenats. Inga problem med patientsäkerheten har noterats och Umecrine Cognition arbetar intensivt tillsammans med sin leverantör f...

March 18, 2025 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Development’s portfolio company AnaCardio has been granted ...

Karolinska Development’s portfolio company AnaCardio has been granted additional EU patent for drug candidate AC01 STOCKHOLM, SWEDEN March 13, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has been granted patent for its drug candidate AC01 as an inotropic agent in the EU. AnaCardio AB is a privately held Swedish clinical-stage biopharmaceutical company developing novel drugs to treat heart failure. The company´s lead asset, AC01, is currently being evaluated in a clinical phase 1b/2a study, GOAL-HF1, in patients with heart fa...

March 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch